Skip to main content
OpenTrials
Completed

NCT Number: NCT04021355

Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African Americans

Experimental data have shown that timing of sodium intake impacts diurnal patterns of sodium excretion. The purpose of this study is to test the hypothesis that the time of day for salt intake impacts (1) blood pressure rhythms and urinary sodium excretion and (2) circadian timing of factors responsible for blood pressure regulation and cardiometabolic health in obese individuals. These studies will address two aims. The first aim will test the hypothesis that limiting high salt intake prior to sleep increases day-night differences in blood pressure, improves timing of urinary sodium excretion, and improves metabolic risk factors. The second aim will test the hypothesis that limiting high salt intake prior to sleep preferentially improves rhythmicity in peripheral vs. central circadian clock factors linked to renal sodium handling. The proposed hypothesis-driven studies will determine how timing of sodium intake affects diurnal blood pressure and circadian timing of factors responsible for blood pressure control and metabolic health, with the ultimate goal of identifying novel strategies to treat nocturnal hypertension and metabolic disease in obesity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama

Birmingham, Alabama, 35294, United States

About this study

Timing of food intake affects a variety of pathophysiological systems. The Western diet, which is high in salt, also contributes to excess morbidity and mortality related to obesity and hypertension. Nocturnal hypertension frequently occurs in obesity and is recognized as an important consequence of hypertension risk, yet the mechanisms involved in this phenomenon are poorly understood. Experimental data from our group have shown that timing of sodium intake impacts diurnal patterns of sodium excretion. Further, we recently reported that high salt intake causes a shift in expression of circadian control genes in the kidney. Additional studies demonstrate that obese animals have an impaired response to a natriuretic stimulus.

Given the established contribution of high salt intake to obesity-dependent hypertension, particularly, nocturnal hypertension, we hypothesize that the time of day for salt intake impacts (1) blood pressure rhythms and urinary sodium excretion and (2) circadian timing of factors responsible for blood pressure regulation and cardiometabolic health in obese individuals. We will conduct a cross-over feeding study of 55 obese adults.

These studies will address two aims. The first aim will test the hypothesis that limiting high salt intake prior to sleep increases day-night differences in blood pressure, improves timing of urinary sodium excretion, and improves metabolic risk factors. We will monitor 24-hour blood pressure by ambulatory blood pressure monitoring to determine the role of timing of sodium intake on diurnal blood pressure patterns. Day- and night-time sodium excretion will be used to determine whether improvements in blood pressure are mediated by enhanced sodium excretion during the day. We will also assess the effects of timing of sodium intake on lipids, leptin, adiponectin, insulin sensitivity, inflammatory cytokines, and immune cell activation over 24 hours.

The second aim will test the hypothesis that limiting high salt intake prior to sleep preferentially improves rhythmicity in peripheral vs. central circadian clock factors linked to renal sodium handling. Circadian measures of plasma cortisol, dim light melatonin onset, and core body temperature (telemetry) will be used to assess the phase and amplitude of the core circadian clock. Circadian measures of peripheral clock genes in buccal cells and peripheral blood monocytes will be used to determine the phase and amplitude of the peripheral clock.

The proposed hypothesis-driven studies will determine how timing of sodium intake affects diurnal blood pressure and circadian timing of factors responsible for blood pressure control and metabolic health, with the ultimate goal of identifying novel strategies to treat nocturnal hypertension and metabolic disease in obesity

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • obese (BMI 30-50 kg/m2)
  • 25-45 years of age

Exclusion criteria

  • evidence of kidney disease (eGFR < 60 ml/min/1.73m2 or abnormal urinalysis)
  • elevated BP (>150/90 mmHg [measured at screening in duplicate after 10min lying recumbent])
  • elevated fasting glucose (>126 g/dL on screening labs)
  • severe anemia (hemoglobin < 8 g/dL for women or < 9 g/dL for men)
  • significant psychiatric illness (as assessed by a validated screening form)
  • past or present drug or alcohol abuse (drug screen)
  • taking 2 or more BP medications or supplements on a regular basis
  • alcohol intake more than 2 drinks/day
  • pregnancy
  • women taking hormone replacement therapy, or post-menopausal women;
  • shift worker
  • sleep disorders (such as sleep apnea assessed by Apnea Link)
  • major chronic disease (e.g., diabetes, lymphocyte disorders)
  • history of smoking or use of tobacco products within the past year
  • use of sleep medications, hypnotics, stimulants, or anti-depressants

Treatment and study plan

Oral sodium supplementation

Other

Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.

Primary outcomes

  1. 24-hour blood pressure

    Time frame: 7 days

    Difference in nocturnal blood pressure between study arms

  2. Core Body Temperature

    Time frame: 7 days

    Difference in core body temperature between study arms

  3. Timing of plasma melatonin increase under dim-light conditions (dim-light melatonin onset)

    Time frame: 8 days

    Difference in the rise of plasma melatonin during the night under dim-light conditions between study arms

Secondary outcomes

  1. 24-hour urinary sodium excretion

    Time frame: 8 days

    Difference in day-night urinary sodium excretion between study arms

  2. Buccal cell clock gene expression (CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2)

    Time frame: 8 days

    Difference in buccal cell clock gene expression (CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2) between study arms. Measures of clock gene expression will all be analyzed as fold change from baseline.

  3. Concentrations of plasma melatonin

    Time frame: 8 days

    Difference in plasma melatonin concentrations between study arms

  4. Concentrations of plasma cortisol

    Time frame: 8 days

    Difference in plasma cortisol concentrations between study arms

  5. Peripheral blood monocyte clock gene (CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2) expression

    Time frame: 8 days

    Difference in peripheral blood monocyte clock gene ((CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2)) expression between study arms. Measures of clock gene expression will all be analyzed as fold change from baseline.

  6. Flow cytometric analysis of circulating immune cells (CD3+, CD4+, CD8+, CD14+, CD45+)

    Time frame: 8 days

    Difference in flow cytometric analysis of circulating immune cells (CD3+, CD4+, CD8+, CD14+, CD45+) between study arms. All flow cytometric analyses will be analyzed as percentage of total nucleated cells.

  7. Concentrations of plasma and urine endothelin 1

    Time frame: 8 days

    Difference in plasma and urine endothelin 1 concentrations between study arms

  8. Concentrations of plasma and urine aldosterone

    Time frame: 8 days

    Difference in plasma and urine aldosterone concentrations between study arms

  9. Concentrations of plasma vasopressin

    Time frame: 8 days

    Difference in plasma vasopressin concentrations between study arms

  10. Concentrations of plasma cytokine (TNA-alpha, IL-1, IL-6, IL-12, IL-17, IL-18, IL-23, IL-10, TGB-beta)

    Time frame: 8 days

    Difference in plasma cytokine measures ((TNA-alpha, IL-1, IL-6, IL-12, IL-17, IL-18, IL-23, IL-10, TGB-beta) between study arms. All cytokine measurements will be analyzed as pg/ml.

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Registry information

Official study title

Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese

Important dates

Study start
2020
Primary completion
2025
Study completion
2025
First posted
Jul 16, 2019
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.